Nitric oxide inhalation - AIT

Drug Profile

Nitric oxide inhalation - AIT

Alternative Names: AIT-BRO; AIT-CF; AIT-COPD; AIT-NTM; AIT-NV; AIT-RSV; AIT-WH; Nitric oxide inhaled; NOxAST; NOxBR; NOxCF; NOxCureBR; NOxCureCF; NOxPN

Latest Information Update: 15 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of British Columbia
  • Developer AIT; Schneider Childrens Medical Center of Israel; University of British Columbia
  • Class Anti-inflammatories; Antiacnes; Antiandrogens; Antibacterials; Antifibrotics; Antifungals; Antihypertensives; Antivirals; Free radicals; Macromolecular substances; Nitrogen oxides; Non-opioid analgesics; Small molecules; Vasodilators
  • Mechanism of Action Androgen receptor antagonists; Angiogenesis inducing agents; Cell death stimulants; Guanylate cyclase stimulants; Nitric oxide donors; Reactive oxygen species modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mycobacterial infections; Cystic fibrosis
  • New Molecular Entity No

Highest Development Phases

  • Phase III Bronchitis
  • Phase II Chronic obstructive pulmonary disease; Cystic fibrosis; Diabetic foot ulcer; Mycobacterial infections; Stroke
  • No development reported Respiratory tract infections
  • Discontinued Asthma; Pneumonia

Most Recent Events

  • 13 Jun 2018 Interim adverse events and efficacy data from the phase III NO-BRO trial for Bronchitis released by AIT Therapeutics
  • 13 Jun 2018 AIT Therapeutics plans a pivotal trial for Bronchiolitis in USA (Inhalation) in the fourth quarter of 2019
  • 23 May 2018 Adverse events data from a phase II trial in Mycobacterial infections (nontuberculous) released by AIT Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top